Analyser av Curasight

Curasight: Brain cancer first indication for uTREAT - Redeye

Redeye gives a short comment on yesterday’s news that Curasight has announced brain cancer as the first indication for uTREAT.

Redeye • 12 Nov 09:02

Curasight Q2: Strategic progress - Redeye

Redeye updates its view of Curasight following the Q2 report and recent events in the company, including an announced financing solution and...

Redeye • 26 Aug 12:50

Curasight: Financing solution announced - Redeye

Redeye comments on Curasight announced financing solution.

Redeye • 19 Jun 12:39

Curasight Q1: Moving forward - Redeye

Redeye updates its view of Curasight following the Q1 report and recent events in the company.

Redeye • 27 May 08:59

Curasight: Rights issue announced – we pause our coverage - Redeye

Redeye briefly comments on Curasight’s rights issue.

Redeye • 13 Feb 13:09

Curasight: First payment from Curium - Redeye

Redeye endorses today’s news that Curasight has received the first milestone payment from Curium and gives an initial comment.

Redeye • 22 Jan 12:58

Curasight: CRO for phase II trial with uTRACE in Prostate cancer in place - Redeye

Redeye endorses the news that Curasight has appointed a CRO, ABX-CRO, to conduct the upcoming phase II trial with uTRACE in prostate cancer,...

Redeye • 14 Dec 2023 09:20

Curasight Q3: Additional data presented - Redeye

Redeye updates its view of Curasight following the Q3 report and recent events in the company.

Redeye • 24 Nov 2023 11:10

Curasight: Theranostics platform with broad potential - Redeye

Redeye initiates coverage of Curasight, a Danish biotech company offering a theranostics platform (therapy + diagnostics) in the field of PE...

Redeye • 25 Oct 2023 08:46

Curasight: Exercise period for warrants starts today - SEB

The exercise period for the warrants of series TO 1 that were issued in connection with Curasight's issue of units during September 2020 sta...

SEB • 16 Sep 2021 10:12

Curasight: Steady progress - SEB

Curasight has reported its Q2/21 quarterly report. The financial P&L is not of great importance for an upcoming biotech company, but it is e...

SEB • 25 Aug 2021 09:21

Curasight Q2: Steady progress with green light to move ahead - SEB